Trial Profile
A 48-Week, Randomized, Open-Label, 2-Arm Study to Compare the Efficacy of Saquinavir/Ritonavir BID Plus Emtricitabine/Tenofovir QD Versus Lopinavir/Ritonavir BID Plus Emtricitabine/Tenofovir QD in Treatment-naive HIV-1 Infected Patients (GEMINI Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Saquinavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir; Ritonavir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms GEMINI
- Sponsors Roche
- 01 Apr 2009 Forty-eight week results published in Journal of Acquired Immune Deficiency Syndromes, April 2009.
- 18 Aug 2008 The trial end date is July 2008, according to Clinicaltrials.gov.
- 26 Oct 2007 Primary endpoint met; results reported at EACS 2007.